EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study

Volker Homberg iD, Dragoș Cătălin Jianu iD, Adina Stan iD, Ștefan Strilciuc iD, Vlad-Florin Chelaru iD, Michał Karliński iD, Michael Brainin iD, Wolf Dieter Heiss, Dafin F Muresanu iD, Pamela M Enderby iD

Stroke · 2025-04 · 56 (4) · 937-947

DOI: 10.1161/strokeaha.124.049834 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Stroke, 2025-04. Verfasst von Volker Homberg und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurorehabilitation, SRH Gesundheitszentrum Bad Wimpfen GmbH, Germany (V.H.). Hauptthemen laut MEDLINE: Ischemic Stroke, Speech Therapy, Amino Acids, Neuroprotective Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Stroke-induced aphasia significantly impacts communication and quality of life. Despite the standard treatment being speech and language therapy, outcomes vary, highlighting the need for additional therapies. Cerebrolysin, a neuroprotective and neurotrophic agent, has shown potential in stroke management. This study addresses the notable gap in research about the combined use of Cerebrolysin and speech therapy, evaluating their synergistic potential in the treatment of aphasia. METHODS: The ESCAS trial (The Efficacy and Safety of Cerebrolysin in the Treatment of Aphasia After Acute Ischemic Stroke), a prospective, randomized-controlled, double-blinded study was conducted in 2 Romanian stroke centers. Participants included those with left middle cerebral artery territory ischemic stroke and nonfluent aphasia, enrolled 3 to 5 days poststroke. Inclusion criteria were right-handedness and Romanian as the mother tongue. Participants received Cerebrolysin or a placebo combined with speech and language therapy in 10-day cycles over 3 intervals, and evaluations were done at baseline, 30, 60, and 90 days respectively. The main outcome measure was Western Aphasia Battery for language function. Changes at days 30, 60, and 90 compared with baseline were quantified, and the effect estimand used was the difference in means between groups. Secondary outcome measurements were the National Institutes of Health Stroke Scale for neurological deficit, the modified Rankin Scale for global disability, and the Barthel Index for activities of daily living. RESULTS: Out of 132 enrolled patients, 123 were included in the intention-to-treat analysis, and 120 in the per-protocol analysis. Overall, both groups showed improvement at subsequent visits compared with the baseline for Western Aphasia Battery and the National Institutes of Health Stroke Scale. The Cerebrolysin group showed greater improvements in Western Aphasia Battery (visit 4 mean increase of 35.579±16.316 [95% CI, 31.289–39.869] points; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ischemic StrokeSpeech TherapyAmino AcidsNeuroprotective AgentsAphasia, BrocaHumansFemaleMalePilot ProjectsMiddle AgedAgedDouble-Blind MethodTreatment OutcomeRecovery of FunctionProspective StudiesCombined Modality TherapyStroke

Stichwörter der Autor:innen

aphasiaischemic strokespeech therapystroke

Substanzen

cerebrolysinAmino AcidsNeuroprotective Agents

Autor:innen und Institutionen

  • Department of Neurorehabilitation, SRH Gesundheitszentrum Bad Wimpfen GmbH, Germany (V.H.).
  • First Division of Neurology, Department of Neurosciences-VIII, "Victor Babeș" University of Medicine and Pharmacy, Timisoara, Romania (D.C.J.).
  • Advanced Centre for Cognitive Research in Neuropsychiatric Pathology (NeuroPsy-Cog), Department of Neurosciences-VIII, "Victor Babeș" University of Medicine and Pharmacy, Timisoara, Romania (D.C.J.).
  • First Department of Neurology, "Pius Brînzeu" Emergency County Hospital, Timisoara, Romania (D.C.J.).
  • Department of Neuroscience, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania (A.S., V.-F.C., D.F.M.).
  • Research Unit, RoNeuro Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania (A.S., S.S., V.-F.C., D.F.M.).

ORCID-Profile: Volker Homberg, Dragoș Cătălin Jianu, Adina Stan, Ștefan Strilciuc, Vlad-Florin Chelaru, Michał Karliński, Michael Brainin, Dafin F Muresanu, Pamela M Enderby

Zitieren

APA

Homberg, V., Jianu, D. C., Stan, A., Strilciuc, Ș., Chelaru, V. F., Karliński, M., Brainin, M., Heiss, W. D., Muresanu, D. F., & Enderby, P. M. (2025). Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study. Stroke, 56(4), 937-947. https://doi.org/10.1161/strokeaha.124.049834

Vancouver

Homberg V, Jianu DC, Stan A, Strilciuc Ș, Chelaru VF, Karliński M, et al. Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study. Stroke. 2025;56(4):937-947. doi:10.1161/strokeaha.124.049834

BibTeX
@article{Homberg2025,
  author = {Homberg, Volker and Jianu, Dragoș Cătălin and Stan, Adina and Strilciuc, Ștefan and Chelaru, Vlad-Florin and Karliński, Michał and Brainin, Michael and Heiss, Wolf Dieter and Muresanu, Dafin F and Enderby, Pamela M},
  title = {Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot Study},
  journal = {Stroke},
  year = {2025},
  volume = {56},
  number = {4},
  pages = {937--947},
  doi = {10.1161/strokeaha.124.049834}
}
Kostenlos starten →